Your browser doesn't support javascript.
loading
Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans.
Seaton, Kelly E; Deal, Aaron; Han, Xue; Li, Shuying S; Clayton, Ashley; Heptinstall, Jack; Duerr, Ann; Allen, Mary A; Shen, Xiaoying; Sawant, Sheetal; Yates, Nicole L; Spearman, Paul; Churchyard, Gavin; Goepfert, Paul A; Maenza, Janine; Gray, Glenda; Pantaleo, Giuseppe; Polakowski, Laura; Robinson, Harriet L; Grant, Shannon; Randhawa, April K; Huang, Ying; Morgan, Cecilia; Grunenberg, Nicole; Karuna, Shelly; Gilbert, Peter B; McElrath, M Juliana; Huang, Yunda; Tomaras, Georgia D.
Afiliación
  • Seaton KE; Duke Human Vaccine Institute, Durham, NC, USA. kelly.seaton@duke.edu.
  • Deal A; Department of Surgery, Duke University, Durham, NC, USA. kelly.seaton@duke.edu.
  • Han X; Department of Immunology, Duke University, Durham, NC, USA. kelly.seaton@duke.edu.
  • Li SS; Department of Molecular Genetics and Microbiology, Duke University, Durham, NC, USA. kelly.seaton@duke.edu.
  • Clayton A; Duke Human Vaccine Institute, Durham, NC, USA.
  • Heptinstall J; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Duerr A; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Allen MA; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Shen X; Duke Human Vaccine Institute, Durham, NC, USA.
  • Sawant S; Department of Surgery, Duke University, Durham, NC, USA.
  • Yates NL; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Spearman P; Division of AIDS, NIAID, NIH, Bethesda, MD, USA.
  • Churchyard G; Duke Human Vaccine Institute, Durham, NC, USA.
  • Goepfert PA; Duke Human Vaccine Institute, Durham, NC, USA.
  • Maenza J; Department of Surgery, Duke University, Durham, NC, USA.
  • Gray G; Duke Human Vaccine Institute, Durham, NC, USA.
  • Pantaleo G; Department of Surgery, Duke University, Durham, NC, USA.
  • Polakowski L; Division of Infectious Diseases, Cincinnati Children's Hospital, Cincinnatti, OH, USA.
  • Robinson HL; Aurum Institute, Johannesburg, South Africa.
  • Grant S; School of Public Health, University of Witwatersrand, Johannesburg, South Africa.
  • Randhawa AK; Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Huang Y; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Morgan C; Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA.
  • Grunenberg N; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Karuna S; South African Medical Research Council, Cape Town, South Africa.
  • Gilbert PB; Service of Immunology and Allergy, and Swiss Vaccine Research Institute, Lausanne University Hospital, Lausanne, Switzerland.
  • McElrath MJ; Division of AIDS, NIAID, NIH, Bethesda, MD, USA.
  • Huang Y; GeoVax Labs, Inc., Smyrna, GA, USA.
  • Tomaras GD; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
NPJ Vaccines ; 6(1): 56, 2021 Apr 15.
Article en En | MEDLINE | ID: mdl-33859204
We studied mucosal immune responses in six HIV-1 vaccine trials investigating different envelope (Env)-containing immunogens. Regimens were classified into four categories: DNA/vector, DNA/vector plus protein, protein alone, and vector alone. We measured HIV-1-specific IgG and IgA in secretions from cervical (n = 111) and rectal swabs (n = 154), saliva (n = 141), and seminal plasma (n = 124) and compared to corresponding blood levels. Protein-containing regimens had up to 100% response rates and the highest Env-specific IgG response rates. DNA/vector groups elicited mucosal Env-specific IgG response rates of up to 67% that varied across specimen types. Little to no mucosal IgA responses were observed. Overall, gp41- and gp140-specific antibodies dominated gp120 mucosal responses. In one trial, prior vaccination with a protein-containing immunogen maintained durability of cervical and rectal IgG for up to 17 years. Mucosal IgG responses were boosted after revaccination. These findings highlight a role for protein immunization in eliciting HIV-1-specific mucosal antibodies and the ability of HIV-1 vaccines to elicit durable HIV-1-specific mucosal IgG.
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Systematic_reviews Idioma: En Revista: NPJ Vaccines Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Systematic_reviews Idioma: En Revista: NPJ Vaccines Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido